Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

Launched by ISALA · Sep 8, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at whether we can safely shorten the time it takes to give certain cancer treatments through an infusion. The treatments being studied include medications like nivolumab, pembrolizumab, and trastuzumab, which are known as monoclonal antibodies. The goal is to see if patients can tolerate these shorter infusion times without experiencing serious side effects.

To be eligible for this study, participants must be 18 years or older, starting treatment with one of the specified medications, and have no history of severe allergic reactions to similar treatments. They should also be willing to sign a consent form agreeing to take part in the study. If you join, you can expect the infusion times to gradually be shortened if it is safe for you. It’s important to note that if you are currently involved in another research study or if your treatment requires strict time and dosage rules, you may not be able to participate in this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Starting treatment with monoclonal antibodies: nivolumab, pembrolizumab ipilimumab, bevacizumab, trastuzumab, durvalumab or atezolizumab.
• • 18 years and older.
• • No known history of increased susceptibility to immunological reactions.
• • Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.
• Exclusion Criteria:
• • Other research medication within 4 weeks of the start of the study.
• • Inclusion in medical research in which the administration of medication should follow its stated times and dosages of infusions
• • Dosage deviates from standard protocol
• • Patients whom receive drugs through a central venous catheter (and for example porth-a-cath).